Palexia - Key
Palexia - Key Visual

YOUR SEVERE CHRONIC LOW BACK PAIN PATIENTS NEED:
STRONG PAIN RELIEF

Palexia® PR offers...

  • 37% more pain reduction than oxycodone/ naloxone3
  • Better symptom control compared to oxycodone/ naloxone3
    • - More reduction of neuropathic pain symptoms3
    • - Less pain attacks3
Palexia - Key Visual - Efficacy

Reduction in
pain intensity
compared to oxycodone/ naloxonea3

Palexia® PR - Reduction in pain intensity - Graph
Zoom

PALEXIA® PR - STRONG PAIN RELIEF3


Palexia - Key Visual - Pain reduction

Changes from baseline in
pain intensity
over timeb3

Palexia® PR - Changes from baseline in pain intensity - Graph
Zoom

PALEXIA® PR - strong pain relief3


Palexia - Key Visual - Symptom control

Reduction in
pain symptomsc3

Palexia® PR - Reduction in pain symptoms - Graph
Zoom

PALEXIA® PR - BETTER SYMPTOM CONTROL COMPARED TO OXYCODONE/NALOXONE3


Palexia - Key Visual - Pain attacks

Pain
attacks
d3

Palexia® PR - Reduction of pain attacks - Graph
Zoom

PALEXIA® PR - MORE PATIENTS WITHOUT PAIN ATTACKS3


View footnotes

a Studied in low back pain with a neuropathic pain component. Primary endpoint: change in pain intensity from baseline to final evaluation (over 12 weeks of treatment).

b Studied in low back pain with a neuropathic pain component. Changes from baseline in pain intensity scores over 12 weeks of treatment.

c Studied in low back pain with a neuropathic pain component. Change from baseline to final evaluation in the NPSI sub-scores.

d Studied in low back pain with a neuropathic pain component. Number of pain attacks during the previous 24 hours as reported on the NPSI at baseline and final evaluation.

ABBREVIATIONS

ANCOVA, analysis of covariance
BL, baseline
cLBP, chronic lower back pain
LOCF, last observation carried foward
LS, least-squares
NP, neuropathic
NPSI, neuropathic pain symptom inventory
NRS-3, numerical rating scale-3
PR, prolonged-release
V, visit
W, week